Tax Reform in This Election Year: It's Not Likely
Which Credit Card Rewards Does the IRS Care About?LifeCell Corporation (NASDAQ: LIFC) provides
surgeons with regenerative and reconstructive tissue matrices for soft tissue repair. Products include AlloDerm, for plastic reconstructive, general surgical, burn and periodontal procedures; Strattice, for plastic reconstructive and general surgical procedures; Graftjacket, for orthopedic applications and lower extremity wounds; Allocraft, for bone grafting procedures; and Repliform, for urogynecologic surgical procedures. The materials are sold in the US and abroad, through a direct sales force and through such distributors as Boston Scientific (NYSE: BSX).
The company pleased investors last week, when it reported Q4 EPS of 19 cents and revenues of $52.6 million. Analysts had been expecting 17 cents and $52.2 million. Management also guided FY08 EPS to $0.98-$1.06 ($1.04 consensus) and FY08 revenues to $233-$243 million ($238.89M consensus). Needham subsequently upgraded the issue to "strong buy" and boosted its price target to $55.
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
